Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$12.00M+159.64%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Hermann Lübbert
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Employees
- 89
- Beta
- 0.84
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -6.17
Financials
Revenue
$12.00M+159.6%Net Income
$-604.0KEBITDA
$-593.0KFree Cash Flow
$-1.66MEPS (diluted)
$-0.05Shares Outstanding (diluted)
12.92M+2053.1%Operating Expenses
$10.12MCash & Debt
$4.67MRevenue by Segment (annual)
$533.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $41.70M | $-10.54M | $-1.04 |
| 2024 | $37.30M | $-17.76M | $-3.22 |
| 2023 | $34.07M | $-20.13M | $-13.02 |
| 2022 | $28.67M | $-640.0K | $-0.61 |
| 2021 | $24.10M | $-37.71M | $-44.10 |
| 2020 | $18.85M | $-10.99M | $-18.94 |
| 2019 | $26.18M | $-10.98M | $-18.09 |
Valuation
BFRIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
30-81.88%Social Signal Score
Mentions (4)
- Newsglobenewswire.com·22d ago·Negative
Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma Ameluz used in conjunction with the RhodoLED lamp becomes the first and only photodynamic therapy approved in the United States to treat a skin cancer, creating an additional growth opportunity for Biofrontera's photodynamic therapy platform
View source ↗ - Newsseekingalpha.com·53d ago·Positive
Biofrontera Inc. (BFRI) Q2 2026 Earnings Call Transcript Biofrontera Inc. (BFRI) Q2 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·53d ago·Neutral
Biofrontera Inc. (BFRI) Reports Q2 Loss, Beats Revenue Estimates Biofrontera Inc. (BFRI) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.57 per share a year ago.
View source ↗ - Newsglobenewswire.com·54d ago·Positive
Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth WOBURN, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the quarter ended June 30, 2026.
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-0.22 per share
Typical surprise -26.7% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.05 vs $-0.10beat
- Thu, May 14$-0.41 vs $-0.18miss
- Thu, Mar 19$0.50 vs $0.20beat
- Wed, Nov 12$-0.59 vs $-0.60beat
- Wed, Aug 13$-0.57 vs $-0.45miss
- Thu, May 15$-0.47 vs $-0.21miss
Estimates and results for BFRI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BFRI officers and directors.
- Bought
- $2
- Sold
- —
1 trade
0 trades
- Biofrontera Agbought
95 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in BFRI.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.